189 related articles for article (PubMed ID: 27755823)
1. Clinical impact of post-progression survival on overall survival in elderly patients with extensive disease small-cell lung cancer.
Imai H; Mori K; Watase N; Kazama T; Fujimoto S; Kaira K; Yamada M; Minato K
Thorac Cancer; 2016 Nov; 7(6):655-662. PubMed ID: 27755823
[TBL] [Abstract][Full Text] [Related]
2. Clinical Significance of the Relationship between Progression-Free Survival or Postprogression Survival and Overall Survival in Patients with Extensive Disease-Small-Cell Lung Cancer Treated with Carboplatin plus Etoposide.
Imai H; Mori K; Watase N; Fujimoto S; Kaira K; Yamada M; Minato K
Can Respir J; 2016; 2016():5405810. PubMed ID: 27445549
[TBL] [Abstract][Full Text] [Related]
3. Individual-level data on the relationships of progression-free survival, post-progression survival, and tumor response with overall survival in patients with advanced non-squamous non-small cell lung cancer.
Imai H; Takahashi T; Mori K; Ono A; Akamatsu H; Shukuya T; Taira T; Kenmotsu H; Naito T; Murakami H; Endo M; Nakajima T; Yamamoto N
Neoplasma; 2014; 61(2):233-40. PubMed ID: 24299320
[TBL] [Abstract][Full Text] [Related]
4. Outcomes of Platinum-Sensitive Small-Cell Lung Cancer Patients Treated With Platinum/Etoposide Rechallenge: A Multi-Institutional Retrospective Analysis.
Genestreti G; Tiseo M; Kenmotsu H; Kazushige W; Di Battista M; Cavallo G; Carloni F; Bongiovanni A; Burgio MA; Casanova C; Metro G; Scarpi E; Korkmaz T; Selcuk S; Roopa K; Califano R
Clin Lung Cancer; 2015 Nov; 16(6):e223-8. PubMed ID: 25983005
[TBL] [Abstract][Full Text] [Related]
5. Baseline quality of life and performance status as prognostic factors in patients with extensive-stage disease small cell lung cancer treated with pemetrexed plus carboplatin vs. etoposide plus carboplatin.
Reck M; Thatcher N; Smit EF; Lorigan P; Szutowicz-Zielinska E; Liepa AM; Winfree KB; Peterson P; Guba SC; Socinski MA
Lung Cancer; 2012 Dec; 78(3):276-81. PubMed ID: 23043970
[TBL] [Abstract][Full Text] [Related]
6. Individual-level data on the relationships of progression-free survival and post-progression survival with overall survival in patients with advanced non-squamous non-small cell lung cancer patients who received second-line chemotherapy.
Imai H; Mori K; Ono A; Akamatsu H; Taira T; Kenmotsu H; Naito T; Kaira K; Murakami H; Endo M; Nakajima T; Takahashi T
Med Oncol; 2014 Aug; 31(8):88. PubMed ID: 24961467
[TBL] [Abstract][Full Text] [Related]
7. Randomized phase II study of carboplatin and etoposide with or without obatoclax mesylate in extensive-stage small cell lung cancer.
Langer CJ; Albert I; Ross HJ; Kovacs P; Blakely LJ; Pajkos G; Somfay A; Zatloukal P; Kazarnowicz A; Moezi MM; Schreeder MT; Schnyder J; Ao-Baslock A; Pathak AK; Berger MS;
Lung Cancer; 2014 Sep; 85(3):420-8. PubMed ID: 24997137
[TBL] [Abstract][Full Text] [Related]
8. Postprogression survival in patients with advanced non-small-cell lung cancer who receive second-line or third-line chemotherapy.
Hayashi H; Okamoto I; Taguri M; Morita S; Nakagawa K
Clin Lung Cancer; 2013 May; 14(3):261-6. PubMed ID: 23107465
[TBL] [Abstract][Full Text] [Related]
9. Randomized phase II study of bevacizumab in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer: results from the SALUTE trial.
Spigel DR; Townley PM; Waterhouse DM; Fang L; Adiguzel I; Huang JE; Karlin DA; Faoro L; Scappaticci FA; Socinski MA
J Clin Oncol; 2011 Jun; 29(16):2215-22. PubMed ID: 21502556
[TBL] [Abstract][Full Text] [Related]
10. Progression-free survival, post-progression survival, and tumor response as surrogate markers for overall survival in patients with extensive small cell lung cancer.
Imai H; Mori K; Wakuda K; Ono A; Akamatsu H; Shukuya T; Taira T; Kenmotsu H; Naito T; Kaira K; Murakami H; Endo M; Nakajima T; Yamamoto N; Takahashi T
Ann Thorac Med; 2015; 10(1):61-6. PubMed ID: 25593610
[TBL] [Abstract][Full Text] [Related]
11. [Therapeutic effects and prognostic factors for the limited-stage small cell lung cancer treated with multidisciplinary therapy].
Dong XJ; Wang MZ; Zhong W; Zhang L; Zhang XT; Zhao J; Xia Y; Li LY
Zhonghua Zhong Liu Za Zhi; 2012 Mar; 34(3):216-21. PubMed ID: 22780978
[TBL] [Abstract][Full Text] [Related]
12. Outcomes of small cell lung cancer patients treated with cisplatin-etoposide versus carboplatin-etoposide.
Karam I; Jiang SY; Khaira M; Lee CW; Schellenberg D
Am J Clin Oncol; 2015 Feb; 38(1):51-4. PubMed ID: 23563211
[TBL] [Abstract][Full Text] [Related]
13. [Comparison of Efficacy and Safety of Different Therapeutic Regimens as
Second-line Treatment for Small Cell Lung Cancer].
Li Z; Liu X; Li J; Gao H; Tang C; Li X; Guo W; Qin H; Wang W; Qu L; Chen J
Zhongguo Fei Ai Za Zhi; 2015 May; 18(5):280-8. PubMed ID: 25975298
[TBL] [Abstract][Full Text] [Related]
14. [Efficiency and adverse effects of the effective therapy applying etoposide + cisplatin and its subsequent maintenance therapy with different durations in patients with small cell lung cancer].
Yang CL; Ma LX; Sun SY; Cui HX; Li ZL; Cheng Y
Zhonghua Zhong Liu Za Zhi; 2016 Jun; 38(6):454-9. PubMed ID: 27346404
[TBL] [Abstract][Full Text] [Related]
15. Survival and Toxicity After Cisplatin Plus Etoposide Versus Carboplatin Plus Etoposide for Extensive-Stage Small-Cell Lung Cancer in Elderly Patients.
Hatfield LA; Huskamp HA; Lamont EB
J Oncol Pract; 2016 Jul; 12(7):666-73. PubMed ID: 27352949
[TBL] [Abstract][Full Text] [Related]
16. Positive Interaction between Prophylactic Cranial Irradiation and Maintenance Sunitinib for Untreated Extensive-Stage Small Cell Lung Cancer Patients After Standard Chemotherapy: A Secondary Analysis of CALGB 30504 (ALLIANCE).
Salama JK; Gu L; Wang X; Pang HH; Bogart JA; Crawford J; Schild SE; Vokes EE; Ready NE
J Thorac Oncol; 2016 Mar; 11(3):361-9. PubMed ID: 26723241
[TBL] [Abstract][Full Text] [Related]
17. Topotecan-carboplatin-etoposide combination as 1st line treatment in patients with small cell lung cancer.
Zarogoulidis K; Mylonaki E; Kakavelas P; Zarogoulidis P; Tsiouda T; Rapti E; Lithoxopoulou H; Zarogoulidou V; Kontakiotis T;
Lung Cancer; 2009 Nov; 66(2):226-30. PubMed ID: 19321222
[TBL] [Abstract][Full Text] [Related]
18. Clinical impact of post-progression survival on overall survival in patients with limited-stage disease small cell lung cancer after first-line chemoradiotherapy.
Kasahara N; Imai H; Kaira K; Mori K; Wakuda K; Ono A; Taira T; Kenmotsu H; Harada H; Naito T; Murakami H; Endo M; Nakajima T; Yamada M; Takahashi T
Radiol Oncol; 2015 Dec; 49(4):409-15. PubMed ID: 26834529
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of maintenance sunitinib following irinotecan and carboplatin as first-line treatment for patients with extensive-stage small-cell lung cancer.
Spigel DR; Greco FA; Rubin MS; Shipley D; Thompson DS; Lubiner ET; Eakle JF; Quinn R; Burris HA; Hainsworth JD
Lung Cancer; 2012 Aug; 77(2):359-64. PubMed ID: 22560921
[TBL] [Abstract][Full Text] [Related]
20. [Chemotherapy-induced myelosuppression and treatment efficacy in extensive-stage small cell lung cancer].
Yashiki C; Hirose T; Okuda K; Yamaoka T; Ohnishi T; Adachi M; Nakamura A
Gan To Kagaku Ryoho; 2009 Nov; 36(11):1839-43. PubMed ID: 19920385
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
